JP2024508372A - 注意欠陥／多動性障害の治療又は予防に使用するための化合物 - Google Patents

注意欠陥／多動性障害の治療又は予防に使用するための化合物 Download PDF

Info

Publication number
JP2024508372A
JP2024508372A JP2023546027A JP2023546027A JP2024508372A JP 2024508372 A JP2024508372 A JP 2024508372A JP 2023546027 A JP2023546027 A JP 2023546027A JP 2023546027 A JP2023546027 A JP 2023546027A JP 2024508372 A JP2024508372 A JP 2024508372A
Authority
JP
Japan
Prior art keywords
compound
adhd
dose
administered
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023546027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508372A5 (https=
Inventor
エーギル カールソン，カール
ソルスタインソン，ハラルドゥル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3Z ehf
Original Assignee
3Z ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2101292.7A external-priority patent/GB202101292D0/en
Priority claimed from GBGB2101291.9A external-priority patent/GB202101291D0/en
Priority claimed from GBGB2101296.8A external-priority patent/GB202101296D0/en
Application filed by 3Z ehf filed Critical 3Z ehf
Publication of JP2024508372A publication Critical patent/JP2024508372A/ja
Publication of JP2024508372A5 publication Critical patent/JP2024508372A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023546027A 2021-01-29 2022-01-28 注意欠陥／多動性障害の治療又は予防に使用するための化合物 Pending JP2024508372A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2101292.7A GB202101292D0 (en) 2021-01-29 2021-01-29 Novel treatments
GBGB2101291.9A GB202101291D0 (en) 2021-01-29 2021-01-29 Novel treatments
GB2101296.8 2021-01-29
GB2101291.9 2021-01-29
GB2101292.7 2021-01-29
GBGB2101296.8A GB202101296D0 (en) 2021-01-29 2021-01-29 Novel treatments
PCT/EP2022/052142 WO2022162199A2 (en) 2021-01-29 2022-01-28 Novel treatments

Publications (2)

Publication Number Publication Date
JP2024508372A true JP2024508372A (ja) 2024-02-27
JP2024508372A5 JP2024508372A5 (https=) 2025-07-17

Family

ID=80682355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546027A Pending JP2024508372A (ja) 2021-01-29 2022-01-28 注意欠陥／多動性障害の治療又は予防に使用するための化合物

Country Status (12)

Country Link
US (1) US20240130995A1 (https=)
EP (1) EP4284356B1 (https=)
JP (1) JP2024508372A (https=)
AU (1) AU2022215118A1 (https=)
CA (1) CA3206935A1 (https=)
ES (1) ES3038949T3 (https=)
HR (1) HRP20250747T1 (https=)
HU (1) HUE071725T2 (https=)
PL (1) PL4284356T3 (https=)
RS (1) RS66934B1 (https=)
SM (1) SMT202500238T1 (https=)
WO (1) WO2022162199A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025093748A1 (en) * 2023-11-03 2025-05-08 3Z Pharmaceuticals Use of a calcium channel blocker in the treatment of adhd

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512339A (ja) * 2003-11-21 2007-05-17 メモリー・ファーマシューティカルズ・コーポレイション 記憶障害の処置における（＋）−イソプロピル２−メトキシエチル４−（２−クロロ−３−シアノ−フェニル）−１，４−ジヒドロ−２，６−ジメチル−ピリジン−３，５−ジカルボキシラートの使用
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
US20110136793A1 (en) * 2008-05-28 2011-06-09 Hoyle Peter C Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
US20150247847A1 (en) * 2012-09-11 2015-09-03 Institució Catalana De Recercai Estudis Avançats Diagnostic method for detecting an autoimmune disease and related subject-matter

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1030672A1 (en) * 1997-11-19 2000-08-30 Merck & Co., Inc. Method for treating attention deficit disorder
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
EP1609783A1 (en) * 2004-06-17 2005-12-28 Neuropharma S.A.U. Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment
WO2014133329A1 (ko) * 2013-02-27 2014-09-04 에스케이케미칼 주식회사 관절염 치료용 복합 제제
KR20140135676A (ko) * 2014-10-02 2014-11-26 한국과학기술원 주의력 결핍 과잉 행동 모델 마우스, 상기 모델 마우스를 이용한 집중력 장애 질병 예방 및 완화 효과 검증 방법, 및 비특이적 ｔ―타입 칼슘 억제제를 함유하는 집중력 장애 질병 예방 및 치료용 조성물
JP2021500416A (ja) * 2017-10-27 2021-01-07 エステベ ファーマスーティカルズ，ソシエダッド アノニマ 疼痛及び疼痛関連状態を治療するための新規アルコキシアミノ誘導体
WO2020120606A1 (en) * 2018-12-12 2020-06-18 Esteve Pharmaceuticals, S.A. New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512339A (ja) * 2003-11-21 2007-05-17 メモリー・ファーマシューティカルズ・コーポレイション 記憶障害の処置における（＋）−イソプロピル２−メトキシエチル４−（２−クロロ−３−シアノ−フェニル）−１，４−ジヒドロ−２，６−ジメチル−ピリジン−３，５−ジカルボキシラートの使用
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
US20110136793A1 (en) * 2008-05-28 2011-06-09 Hoyle Peter C Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
US20150247847A1 (en) * 2012-09-11 2015-09-03 Institució Catalana De Recercai Estudis Avançats Diagnostic method for detecting an autoimmune disease and related subject-matter

Also Published As

Publication number Publication date
CA3206935A1 (en) 2022-08-04
SMT202500238T1 (it) 2025-07-22
PL4284356T3 (pl) 2025-07-28
WO2022162199A2 (en) 2022-08-04
EP4284356A2 (en) 2023-12-06
HUE071725T2 (hu) 2025-09-28
HRP20250747T1 (hr) 2025-08-15
AU2022215118A1 (en) 2023-08-17
AU2022215118A9 (en) 2024-05-16
EP4284356B1 (en) 2025-04-02
EP4284356C0 (en) 2025-04-02
RS66934B1 (sr) 2025-07-31
US20240130995A1 (en) 2024-04-25
WO2022162199A3 (en) 2022-09-15
ES3038949T3 (en) 2025-10-16

Similar Documents

Publication Publication Date Title
EP2167066B1 (en) Droxidopa and pharmaceutical composition thereof for the treatment of attention deficit disorders
US20170304351A1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
TW202327571A (zh) 精神作用醫藥及其用於治療精神及神經病狀及病症之用途
JP2024508372A (ja) 注意欠陥／多動性障害の治療又は予防に使用するための化合物
JPH1045582A (ja) アルツハイマー病の早期発病患者を治療するためのカルニチン誘導体を含む医薬
JP2023549394A (ja) 注意欠陥／多動性障害の新規な治療
TW202345789A (zh) 精神作用醫藥及其用於治療精神及神經病狀及病症之用途
US12042493B2 (en) Pharmaceutical compounds for use in treating Huntington's disease
WO2025093748A1 (en) Use of a calcium channel blocker in the treatment of adhd
CN117120046A (zh) 用于治疗注意力缺陷多动障碍的化合物
HK40101538B (en) Compounds for use in the treatment of attention deficit hyperactivity disorder
HK40101538A (en) Compounds for use in the treatment of attention deficit hyperactivity disorder
CN116981460A (zh) 注意力缺陷/多动障碍的新颖治疗
US20180042919A1 (en) PARP Inhibitors for the Treatment of Major Depressive Disorder and Related Conditions
CN118434416A (zh) 精神作用药物及其用于治疗精神和神经病状和病症的用途
HK40092010A (zh) GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法
CN117957003A (zh) 治疗神经退行性疾病的方法
Kamath Study of Anticonvulsant Effect of Simvastatin in Maximal Electroshock and Pentylenetetrazole Induced Seizure Model in Albino Mice

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250709

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260130

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260422